Funding sources and Conflicts of Interest

Funding sources

ISA2019 Madrid is organised by the International Stillbirth Alliance (United States) and Umamanita (Local organiser, Spain), both of whom are non-profit organisations. The conference is funded by income from  three primary sources:

  • Delegates fees
  • Organisers’ funds (Umamanita and International Stillbirth Alliance)
  • Sponsorship, which can be divided into
    a) 1 commercial sponsor: Owletcare
    b) 4 non-commercial sponsors: Feileacain (Irish Stillbirth and Neonatal Death Charity), Ciaolapo (Italian Stillbirth and Neonatal Death Charity), Starlegacy (Stillbirth and Neonatal Death Charity in the USA), University of Utah, 

Conflicts of Interests statements

Ensuring the impartiality of scientific content is a key mission of the International Stillbirth Alliance’s annual conferences.  

As part of the International Stillbirth Alliances ethics policy and to comply with European Accreditation Council for Continuing Medical Education (EACCME®) accreditation requirements all members of the Organising and Scientific Committees, Speakers and Poster presenters are asked to declare any actual or potential conflicts of interests, such as economic or other relationships with pharmaceutical or other commercial entities that might introduce bias to the presentation of scientific content.

At the beginning of each individual presentation each speaker must clearly state if they have any actual or potential conflicts of interest (COIs). If any COIs do exist they should briefly describe them. 

Following the ethics process 3 speakers declared actual or potential conflicts of interest:

Prof. Stephen Tong and colleagues
Presentation title: Circulating SPINT1 is a biomarker of pregnancies with poor placental function, fetal growth restriction, and at higher risk of stillbirth.
Scientific session: Breakout: Perinatal mortality prevention strategies (Saturday 6th)
Speaker type: Selected from abstract submissions
COIs: Stephen Tong (and named co-authors on the associated abstract) hold a provisional patent (# 2018901813) relating to the use of SPINT1 and syndecan as diagnostic markers in pregnancy. A named co-author on the submitted abstract (N. Haan) is the owner of Foresight Health, which has a research and commercialisation agreement with The University of Melbourne relating to the development of diagnostic markers of placental insufficiency, and rights to the patent.

Prof. Gordon Smith
Presentation title: Discovering novel predictors for fetal growth restriction
Scientific session: Keynote 4 (Sunday 6th)
Speaker type: Invited
COIs: Gordon Smith receives/has received research support from GE (supply of two diagnostic ultrasound systems) and Roche (supply of equipment and reagents for biomarker studies). Gordon Smith has been paid to attend advisory boards by GSK and Roche. GS has acted as a paid consultant to GSK. Gordon Smith has received support to attend a scientific meeting from Chiesi. Gordon Smith is named as co-inventor in a patent submitted by Cambridge Enterprise (UK)  in the national phase, for a novel treatment for preterm infants (US61/253936). Gordon Smith is named inventor in a patent submitted by GSK (UK), for novel application of an existing GSK compound for the prevention of preterm birth (PCT/EP2014/062602).

Prof. Ingela Radestad
Presentation title: Supporting parenthood when a baby is stillborn
Scientific session: Breakout: Parents’ experiences of care: listening to parents and understanding their needs
Speaker type: Invited
COIs: Ingela Radestad has invented Cubitus baby and is awarded royalties from the company that produces the tool.